Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Mutated Ras and Raf kinases are established drivers of cancer metastasis via the Ras/Raf/MEK/ERK (MAPK) pathway.
• The role of non-mutated (wild-type) Raf in metastasis is increasingly recognized, but its underlying mechanisms are not fully understood.
• Elevated expression of wild-type Raf family members (C-Raf, A-Raf, or B-Raf) can independently promote metastatic processes.

Purpose of the Study:

• To investigate the role of wild-type C-Raf in promoting cancer metastasis.
• To elucidate the specific mechanisms by which wild-type C-Raf contributes to metastasis.
• To identify potential therapeutic targets for treating metastatic disease based on C-Raf function.

Main Methods:

• Utilized an in vivo model to assess the impact of wild-type C-Raf overexpression on prostate cell metastasis.
• Performed transcriptomic and phosphoproteomic analyses to understand signaling alterations.
• Employed C-Raf mutants and endogenous Raf monomer knockouts to dissect the role of kinase activity and dimerization.

Main Results:

• Wild-type C-Raf overexpression promoted metastasis in a gene dosage-dependent manner.
• C-Raf-driven metastasis correlated with upregulated MAPK signaling.
• C-Raf's dimerization domain, not its kinase activity, was essential for promoting metastasis.
• C-Raf's ability to form heterodimers with other Raf molecules was crucial for its pro-metastatic function.

Conclusions:

• Wild-type C-Raf promotes cancer metastasis through dimerization-dependent signaling, independent of its kinase activity.
• C-Raf heterodimer formation is a key mechanism driving metastasis.
• Targeting wild-type C-Raf heterodimer signaling presents a promising therapeutic strategy for managing metastatic cancers.